Deutsche Bank downgrades Novartis stock rating to sell on valuation

Deutsche Bank downgraded Novartis to Sell from Hold and cut its price target to CHF115 from CHF120, citing a mixed third quarter, valuation concerns after the rally, and limited expected near-term catalysts. Novartis shares had recovered losses after setbacks involving pelacarsen and delucemdostat and were 6% below their 52-week high; the stock trades at a 31.11 P/E and was described as overbought by RSI indicators. Q3 core EPS of $2.46 beat the $2.28 forecast, while revenue of $14.52B missed the $14.60B estimate; Novartis raised its profit outlook.

Analysis

The setup is primarily about expectations and positioning, not evidence of a new deterioration in Novartis’s operating trajectory. A rally alongside raised profit guidance gives the stock support, but if investors have already priced modestly positive pipeline and investor-day outcomes, those events may need to exceed—not merely meet—expectations to extend the rerating. That makes event risk asymmetric: a strong result may have limited incremental valuation impact, while disappointing data or an unconvincing outlook can unwind the recent recovery. The reported EPS/revenue split also argues against treating cost control as a substitute for sustained top-line delivery.

Near term (days to year-end), rotation into pharma and event positioning can dominate fundamentals; a single broker downgrade is not, by itself, a durable earnings signal. Over 1–3 months, watch remibrutinib data and capital-markets-day guidance for changes to pipeline probabilities or forward estimates. Over 6–18 months, the key question is whether newer medicines can sustain growth enough to support a premium multiple. A sector-wide rotation could lift Novartis despite company-specific risk, so a standalone short has meaningful factor exposure. Deutsche Bank’s research call does not establish a separate investment thesis in DB.

Key Decisions for Investors

• Consider a modest NVS underweight versus a diversified pharma/healthcare basket rather than an outright short; the thesis is that event expectations leave less upside surprise and more downside if execution disappoints. Keep sizing small because raised profit guidance and sector inflows can overwhelm the valuation argument.
• Avoid adding to NVS solely on the recent recovery. Reassess after remibrutinib data and the capital markets day: look for changes in forward revenue/profit guidance and evidence that pipeline prospects materially alter the medium-term growth path.
• Falsification: close the relative underweight if Novartis delivers positive catalysts accompanied by upward estimate revisions and sustained relative outperformance. Escalate caution if data disappoint, guidance weakens, or the stock loses its post-earnings recovery while pharma peers remain firm.
• Before using options to express downside, verify implied volatility, skew, and event pricing; the article provides no options or valuation-comparables data to support a defined-risk structure.